These results raise fascinating questions that we may not know the answer to for a long time.
How much can the drug improve a patient?
Does improvement keep occurring indefinitely?
What is most intriguing is can the drug prevent the onset and development of the neurological affect altogether if treatment commenced at its onset (6-18 months of age)?
Maybe screening for deficiencies in MECP2 should be routine in infancy?
So in other words do we have a treatment or a cure, and if it is “just” a treatment can it mimic a cure if treatment is initiated early enough?
Ann: Positive topline results from Phase 3 trial in Rett syndrome, page-47
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.57 |
Change
2.170(15.1%) |
Mkt cap ! $2.117B | |||
| Open | High | Low | Value | Volume |
| $14.85 | $16.67 | $14.60 | $24.77M | 1.544M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1500 | $16.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.57 | 1717 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |